Phosphodiesterase type-2 and NO-dependent S-nitrosylation mediate the cardioinhibition of the antihypertensive catestatin

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 2, 2012, Pages

  Angelone, Tommaso ^a   Quintieri, Anna Maria ^a   Pasqua, Teresa ^a   Gentile, Stefano ^a   Tota, Bruno ^a   Mahata, Sushil K ^b   Cerra, Maria Carmela ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

arrestin; 2 3 adrenergic receptors; Nitric oxide; Phospholamban; Signal transduction

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 2 MORPHOLINO 8 PHENYLCHROMONE; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ARRESTIN; CATESTATIN; CHROMOGRANIN A; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NADOLOL; NEBIVOLOL; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLAMBAN; SPLEEN EXONUCLEASE; TYLOXAPOL; WORTMANNIN;

ADRENERGIC STIMULATION; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE RELEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; HEART FUNCTION; HEART PROTECTION; INOTROPISM; ISOLATED HEART; MALE; NITROSYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARRESTINS; CALCIUM-BINDING PROTEINS; CARDIOVASCULAR AGENTS; CHROMOGRANIN A; EXONUCLEASES; HEART; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDE FRAGMENTS; PHOSPHATIDYLINOSITOL 3-KINASES; RATS; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 84855338182     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00491.2011     Document Type: Article

References (84)

1. Aardal S, Helle KB, Elsayed S, Reed RK, Serck-Hanssen G. Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J Neuroendocrinol 5: 405-412, 1993.
2. Angelone T, Quintieri AM, Brar BK, Limchaiyawat PT, Tota B, Mahata SK, Cerra MC. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 149: 4780-4793, 2008.
3. Angelone T, Filice E, Quintieri AM, Imbrogno S, Recchia A, Pulerà E, Mannarino C, Pellegrino D, Cerra MC. Beta3-adrenoceptors modulate left ventricular relaxation in the rat heart via the NO-cGMP-PKG pathway. Acta Physiol (Oxf) 193: 229-39 2008.
4. Biswas N, Curello E, O'Connor DT, Mahata SK. Chromogranin/ secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin [Chga(364-384)]. Cell Tissue Res 342: 353-361, 2010.
5. Brás-Silva C, Leite-Moreira AF. Modulation of the myocardial effects of selective ETB receptor stimulation and its implications for heart failure. Rev Port Cardiol 24: 1125-1133, 2005.
6. Cerra MC, Pellegrino D. Cardiovascular cGMP-generating systems in physiological and pathological conditions. Curr Med Chem 14: 585-599, 2007.
7. Choi BM, Pae HO, Jang SI, Kim YM, Chung HT. Nitric oxide as a pro-apoptotic as well as anti-apoptotic modulator. J Biochem Mol Biol 35: 116-126, 2002.
8. De Nigris F, Rienzo M, Schiano C, Fiorito C, Casamassimi A, Napoli C. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. Eur J Cancer 44: 334-40, 2008.
9. Desjardins F, Balligand JL. Nitric oxide-dependent endothelial function and cardiovascular disease. Acta Clin Belg 61: 326-34, 2006.
10. Dev NB, Gayen JR, O'Connor DT, Mahata SK. Chromogranin A and the autonomic system: decomposition of heart rate variability by time and frequency domains, along with non-linear characteristics during chromogranin A ablation, with "rescue" by its catestatin. Endocrinology 151: 2760-2768, 2010.
11. Drake MT, Shenoy SK, Lefkowitz RJ. Trafficking of G proteincoupled receptors. Circ Res 99: 570-582, 2006.
12. Durham WJ, Aracena-Parks P, Long C, Rossi AE, Goonasekera SA, Boncompagni S, Galvan DL, Gilman CP, Baker MR, Shirokova N, Protasi F, Dirksen R, Hamilton SL. RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice. Cell 133: 53-65, 2008.
13. Egger M, Beer AG, Theurl M, Schgoer W, Hotter B, Tatarczyk T, Vasiljevic D, Frauscher S, Marksteiner J, Patsch JR, Schratzberger P, Djanani AM, Mahata SK, Kirchmair R. Monocyte migration: a novel effect and signaling pathways of catestatin. Eur J Pharmacol 598: 104-111, 2008.
14. Faucher FA, Gannier FE, Lignon JM, Cosnay P, Malécot. Roles of PKA, PI3K, and cPLA2 in the NO-mediated negative inotropic effect of beta2-adrenoceptor agonists in guinea pig right papillary muscles. Am J Physiol Cell Physiol 294: C106-C117, 2008.
15. Filice E, Recchia AG, Pellegrino D, Angelone T, Maggiolini M, Cerra MC. A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat. J Physiol Pharmacol 60: 3-10, 2009.
16. Fischmeister R, Castro LR, Abi-Gerges A, Rochais F, Jurevicious J, Leroy J, Vandecasteele G. Compartmentation of cyclic nucleotide signaling in the heart. The role of cyclic nucleotide phosphodiesterases. Circ Res 99: 816-828, 2006.
17. Froehlich JP, Mahaney JE, Keceli G, Pavlos CM, Goldstein R, Redwood AJ, Sumbilla C, Lee DI, Tocchetti CG, Kass DA, Paolocci N, Toscano JP. Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl. Biochemistry 47: 13150-13152, 2008.
18. Fung MM, Salem RM, Mehtani P, Thomas B, Lu CF, Perez B, Rao F, Stridsberg M, Ziegler MG, Mahata SK, O'Connor DT. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens 32: 278-287, 2010.
19. Gaede AH, Pilowsky PM. Catestatin in rat RVLM is sympathoexcitatory, increases barosensitivity, and attenuates chemosensitivity and the somatosympathetic reflex. Am J Physiol Regul Integr Comp Physiol 299: R1538-R1545, 2010.
20. Gallo MP, Levi R, Ramella R, Brero A, Boero O, Tota B, Alloatti G. Endothelium-derived nitric oxide mediates the antiadrenergic effect of human vasostatin-1 in rat ventricular myocardium. Am J Physiol Heart Circ Physiol 292: H2906-H2912, 2007.
21. Garofalo F, Parisella ML, Amelio D, Tota B, Imbrogno S. Phospholamban S-nitrosylation modulates Starling response in fish heart. Proc Biol Sci 276: 4043-4052, 2009.
22. Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, Bril A, Balligand JL, Le Marec H. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 102: 1377-1384, 1998.
23. Gauthier C, Tavernier G, Trochu JN, Leblais V, Laurent K, Langin D, Escande D, Le Marec H. Interspecies differences in the cardiac negative inotropic effects of beta(3)-adrenoceptor agonists. J Pharmacol Exp Ther 290: 687-693, 1999.
24. Gauthier C, Langin D, Balligand JL. β3-Adrenoceptors in the cardiovascular system. J Clin Invest 21: 426-430, 2000.
25. Gayen JR, Gu Y, O'Connor DT, Mahata SK. Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin A null mouse. Endocrinology 150: 5027-5035, 2009.
26. Gayen JR, Zhang K, Ramachandrarao SP, Mahata M, Chen Y, Kim HS, Naviaux RK, Sharma K, Mahata SK, O'Connor DT. Role of reactive oxygen species in hyperadrenergic hypertension: Biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin A gene. Circ Cardiovasc Genet 3: 414-425, 2010.
27. Hartell NA, Archer HE, Bailey CJ. Insulin-stimulated endothelial nitric oxide release is calcium independent and mediated via protein kinase B. Biochem Pharmacol 69: 781-790, 2005.
28. Haworth RS, Cuello F, Avkiran M. Regulation by phosphodiesterase isoforms of protein kinase A-mediated attenuation of myocardial protein kinase D activation. Basic Res Cardiol 106: 51-63, 2011.
29. Hassanabad ZF, Furman BL, Parratt JR, Aughey E. Coronary endothelial dysfunction increases the severity of ischaemia-induced ventricular arrhythmias in rat isolated perfused hearts. Basic Res Cardiol 93: 241-249, 1998.
30. Hattori Y. Cardiac histamine receptors: their pharmacological consequences and signal transduction pathways. Methods Find Exp Clin Pharmacol 21: 123-131, 1999.
31. Helle KB. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev Camb Philos Soc 79: 769-794, 2004.
32. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 6: 150-166, 2005.
33. Imbrogno S, Garofalo F, Cerra MC, Mahata SK, Tota B. The catecholamine release-inhibitory peptide catestatin (chromogranin A344-364) modulates myocardial function in fish. J Exp Biol 213: 3636-3643, 2010.
34. Just A, Olson AJ, Arendshorst WJ. Dual constrictor and dilator actions of ET(B) receptors in the rat renal microcirculation: interactions with ET(A) receptors. Am J Physiol Renal Physiol 286: F660-F668, 2004.
35. Kennedy BP, Mahata SK, O'Connor DT, Ziegler MG. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 19: 1241-1248, 1998.
36. Kennedy RH, Owings R, Shekhawat N, Joseph J. Acute negative inotropic effects of homocysteine are mediated via the endothelium. Am J Physiol Heart Circ Physiol 287: H812-H817, 2004.
37. Kots AY, Martin E, Sharina IG, Murad F. A short history of cGMP, guanylyl cyclases, and cGMP-dependent protein kinases. Hand Exp Pharmacol 191: 1-14, 2009.
38. Krüuger PG, Mahata SK, Helle KB. Catestatin (chromogranin A344-358) stimulates release of histamine from rat pleural and peritoneal mast cells. Ann NY Acad Sci 971: 349-51, 2002.
39. 2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest 118: 2230-2245, 2008.
40. Leite-Moreira AF, Brás-Silva C, Pedrosa C. Myocardial effects of ETB receptor stimulation. Rev Port Cardiol 21: 1009-1016, 2002.
41. Mahapatra NR, O'Connor DT, Vaingankar SM, Sinha Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegler MG, Ross J Jr, Mahata SK. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 115: 1942-1952, 2005.
42. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ. Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 100: 1623-1633, 1997.
43. Mahata SK, Mahata M, Wakade AR, O'Connor DT. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A344-364): identification of amino acid residues crucial for activity. Mol Endocrinol 14: 1525-1535, 2000.
44. Mahata SK, Mahata M, Fung MM, O'Connor DT. Catestatin: a multifunctional peptide from chromogranin A. Regul Pept 162: 33-43, 2010.
45. Martinez-Ruiz A, Villanueva L, Gonzalez de Orduna C, Lopez-Ferrer D. S nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc Natl Acad Sci USA 102: 8525-8530, 2005.
46. Massion PB, Dessy C, Desjardins F, Pelat M, Havaux X, Belge C, Moulin P, Guiot Y, Feron O, Janssens S, Balligand JL. Cardiomyocyterestricted overexpression of endothelial nitric oxide synthase (NOS3) attenuates beta-adrenergic stimulation and reinforces vagal inhibition of cardiac contraction. Circulation 110: 2666-2672, 2004.
47. Massion PB, Pelat M, Belge C, Balligand JL. Regulation of the mammalian heart function by nitric oxide. Comp Biochem Physiol A Mol Integr Physiol 142: 144-150, 2005.
48. Matsuda N, Jesmin S, Takahashi Y, Hatta E, Kobayashi M, Matsuyama K, Kawakami N, Sakuma I, Gando S, Fukui H, Hattori Y, Levi R. Histamine H1 and H2 receptor gene and protein levels are differentially expressed in the hearts of rodents and humans. J Pharmacol Exp Ther 309: 786-795, 2004.
49. Mazza R, Gattuso A, Mannarino C, Brar BK, Barbieri SF, Tota B, Mahata SK. Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart. Am J Physiol Heart Circ Physiol 295: H113-H122, 2008.
50. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, Pozzan T, Kass DA, Paolocci N, Houslay MD, Zaccolo M. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res 98: 226-234, 2006.
51. Montero-Hadjadje M, Vaingankar S, Elias S, Tostivint H, Mahata SK, Anouar Y. Chromogranins A and B and secretogranin II: evolutionary and functional aspects. Acta Physiol (Oxf) 192: 309-324, 2008.
52. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 78: 1-5, 1986.
53. Neidhold S, Eichhorn B, Kasper M, Ravens U, Kaumann AJ. The function of alpha-and betaadrenoceptors of the saphenous artery in caveolin-1 knockout and wild-type mice. Br J Pharmacol 150: 261-270, 2007.
54. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, et al. beta-Arrestin-mediated beta(1)-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117: 2445-2458, 2007.
55. O'Connor DT, Takiyyuddin MA, Printz MP, Dinh TQ, Barbosa JA, Rozansky DJ, Mahata SK, Wu H, Kennedy BP, Ziegler MG, Wright FA, Schlager G, Parmer RJ. Catecholamine storage vesicle protein expression in genetic hypertension. Blood Press 8: 285-295, 1999.
56. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 20: 1335-1345, 2002.
57. O'Connor DT, Zhu G, Rao F, Taupenot L, Fung MM, Das M, Mahata SK, Mahata M, Wang L, Zhang K, Greenwood TA, Shih PA, Cockburn MG, Ziegler MG, Stridsberg M, Martin NG, Whitfield JB. Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure. Circulation 118: 247-57, 2008.
58. Ozawa K, Whalen EJ, Nelson CD, Mu Y, Hess DT, Lefkowitz RJ, Stamler JS. S-nitrosylation of beta-arrestin regulates beta-adrenergic receptor trafficking. Mol Cell 31: 395-405, 2008.
59. Penna C, Alloatti G, Gallo MP, Cerra MC, Levi R, Tullio F, Bassino E, Dolgetta S, Mahata SK, Tota B, Pagliaro P. Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell Mol Neurobiol 30: 1171-1179, 2010.
60. Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, Cerra MC, Bellocci F, Crea F, Maseri A. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 28: 1117-1127, 2007.
61. Ramella R, Boero O, Alloatti G, Angelone T, Levi R, Gallo MP. Vasostatin 1 activates eNOS in endothelial cells through a proteoglycandependent mechanism. J Cell Biochem 110: 70-79, 2010.
62. Reddy LG, Autry JM, Jones LR, Thomas DD. Co-reconstitution of phospholamban mutants with Ca-ATPase reveals dependence of inhibitory function on phospholamban structure. J Biol Chem 274: 7649-7655, 1999.
63. Reiter E, Lefkowitz RJ. GRKs and b-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab 17: 159-165, 2006.
64. Salie R, Moolman JA, Lochner A. The role of β-adrenergic receptors in the cardioprotective effects of beta-preconditioning (βPC). Cardiovasc Drugs Ther 25: 31-46, 2011.
65. Sears CE, Bryant SM, Ashley EA, Lygate CA, Rakovic S, Wallis HL, Neubauer S, Terrar DA, Casadei B. Cardiac neuronal nitric oxide synthase isoform regulates myocardial contraction and calcium handling. Circ Res 92: e52-9, 2003.
66. Seddon MD, Chowienczyk PJ, Brett SE, Casadei B, Shah AM. Neuronal nitric oxide synthase regulates basal microvascular tone in humans in vivo. Circulation 117: 1991-1996, 2008.
67. Schmidt AG, Edes I, Kranias EG. Phospholamban: a promising therapeutic target in heart failure? Cardiovasc Drugs Ther 15: 387-396, 2001.
68. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol 64: 749-774, 2002.
69. Skeberdis VA. Structure and function of beta3-adrenergic receptors. Medicina (Kaunas) 40: 407-413, 2004.
70. Steiner HJ, Weiler R, Ludescher C, Schmid KW, Winkler H. Chromogranins A and B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J Histochem Cytochem 38: 845-850, 1990.
71. Sun J, Murphy E. Protein S-nitrosylation and cardioprotection. Circ Res 106: 285-96, 2010.
72. Taupenot L, Harper KL, O'Connor DT. Mechanisms of disease: the chromogranin-secretogranin family. N Engl J Med 348: 1134-1149, 2003.
73. Tota B, Angelone T, Mazza R, Cerra MC. The chromogranin A-derived vasostatins: new players in the endocrine heart. Curr Med Chem 15: 1444-1451, 2008.
74. Tota B, Cerra MC, Gattuso A. Catecholamines, cardiac natriuretic peptides and chromogranin A: evolution and physiopathology of a "whip-brake" system of the endocrine heart. J Exp Biol 213: 3081-3103, 2010.
75. Trochu JN, Leblais V, Rautureau Y, Bévérelli F, Le Marec H, Berdeaux A, Gauthier C. Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br J Pharmacol 128: 69-76, 1999.
76. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of betaadrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 87: 454-463, 1993.
77. Wakeno-Takahashi M, Otani H, Nakao S, Imamura H, Shingu K. Isoflurane induces second window of preconditioning through upregulation of inducible nitric oxide synthase in rat heart. Am J Physiol Heart Circ Physiol 289: H2585-H25891, 2005.
78. Weiergräber M, Pereverzev A, Vajna R, Henry M, Schramm M, Nastainczyk W, Grabsch H, Schneider T. Immunodetection of alpha1E voltage-gated Ca(2+) channel in chromogranin-positive muscle cells of rat heart, and in distal tubules of human kidney. J Histochem Cytochem 48: 807-819, 2000.
79. Whalen EJ, Foster MW, Matsumoto A, Ozawa K, Violin JD, Que LG, Nelson CD, Benhar M, Keys JR, Rockman HA, Koch WJ, Daaka Y, Lefkowitz RJ, Stamler JS. Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell 129: 511-522, 2007.
80. Winkler H, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 49: 497-528, 1992.
81. Xiang Y, Kobilka BK. Myocyte adrenoceptor signaling pathways. Science 300: 1530-1532, 2003.
82. Xiao RP, Cheng H, Zhou YY, Kuschel M, Lakatta EG. Recent advances in cardiac beta(2)-adrenergic signal transduction. Circ Res 85: 1092-1100, 1999.
83. Yano N, Ianus V, Zhao TC, Tseng A, Padbury JF, Tseng YT. A novel signaling pathway for β-adrenergic receptor-mediated activation of phosphoinositide 3-kinase in H9c2 cardiomyocytes. Am J Physiol Heart Circ Physiol 293: H385-H393, 2007.
84. Zucker IH. Novel mechanisms of sympathetic regulation in chronic heart failure. Hypertension 48: 1005-1011, 2006.